Akiko Tohgo

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

Marc Maliepaard, Margôt A. van Gastelen, Akiko Tohgo et al. · PubMed · 2001 · 234 citations

Breast Oncology, Chemoprevention Strategy, Bcrp-mediated Resistance +17

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

Eiji Kumazawa, Takeshi Jimbo, Yusuke Ochi et al. · Cancer Chemotherapy and Pharmacology · 1998 · 79 citations

Tumor Biology, Drug Targeting, Oncology +9

DJ‐927, a novel oral taxane, overcomes P‐glycoprotein‐mediated multidrug resistance <i>in vitro</i> and <i>in vivo</i>

Motoko Shionoya, Takeshi Jimbo, Mayumi Kitagawa et al. · Cancer Science · 2003 · 76 citations · Full text

DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant

Noriko Joto, Mineko Ishii, Megumi Minami et al. · International Journal of Cancer · 1997 · 70 citations · Full text

Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6

Michio Iwahana, Ikuo Mitsui, Akiko Tohgo et al. · Anti-Cancer Drugs · 2000 · 65 citations

Glutathione Content, Metronomic Chemotherapy, Tumor Biology +16